CSNK1A1 and mantle cell lymphoma: We aimed at i) assessing the effect of CK1α inactivation on the proliferation, survival, sensitivity to therapeutic agents and intracellular signaling of MCL cells, ii) evaluating CK1α involvement in the BCR cascade and in sustaining MCL cell “addiction” to the BCR; iii) evaluating if CK1α inhibition could empower BCR inhibitors (such as Ibrutinib and Duvelisib) cytotoxicity for the treatment of MCL.